The global Research Antibodies Market is estimated to be valued at US$ 3785.5 Bn or Bn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Research antibodies are proteins produced by B-cells that recognize and bind to foreign objects like bacteria, viruses or detect tumor cells. They are used for various important research applications in proteomics, genomics and drug discovery. With the growing biomedical research and healthcare industry, demand for research antibodies is increasing.
Market key trends:
One of the key trends in the research antibodies market is development of recombinant antibodies. Traditional hybridoma technology is time consuming and laborious. Companies are focusing on developing cost effective recombinant antibodies using technologies like phage display, transgenic animals etc which can generate antibodies in large quantities and with high affinity and specificity. Recombinant antibodies have advantages like well defined structure, batch to batch consistency, long shelf life which is driving their adoption in research activities. This trend is expected to continue over the forecast period.
SWOT Analysis
Strength: Presence of large number of major market players with strong financial capabilities for investments in R&D. Weakness: High costs associated with production and procurement of research antibodies. Opportunity: Rising demand for disease-specific biomarker antibodies and increasing healthcare expenditure provides growth opportunities. Threats: Stringent regulatory requirements for approval and commercialization of antibodies.
Key Takeaways
Global Research Antibodies Market Size in 2023 is expected to reach US$ 3785.5 Bn, growing at a CAGR of 5.9% over the forecast period owing to rising investment in development of novel antibodies for treatment of various diseases.
Regional analysis: North America dominates the global market, with the largest market share, followed by Europe. The market in Asia Pacific is expected to witness highest growth during the forecast period.
Key players: Thermo Fisher Scientific Inc, Bio-rad Laboratories, Lonza Group, Merck Millipore, Cell Signalling Technology Inc., F.Hoffmann La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company, Agilent Technologies, Danaher Corporation, BioLegend Inc., Illumina, Phoenix Pharmaceuticals, Abcam plc
